Encephalopathy News and Research

RSS

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

Pfizer Inc. announced today that the European Commission (EC) has granted marketing authorization for INLYTA (axitinib) for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of kidney cancer, after failure of prior treatment with sunitinib or a cytokine.

4 Sep 2012

Sleep disorder treatment: an interview with Dr Seth Lederman, President and CEO of Tonix Pharmaceuticals

Sleep disorders are a large area. We are focused on one particular type of sleep disturbance called “non-restorative” sleep. People with this problem do sleep, but they don’t wake up feeling refreshed or feeling that their sleep has had the restorative effects of healthy sleep.

29 Aug 2012

Neuralstem completes NSI-566 Phase I trial on amyotrophic lateral sclerosis

Neuralstem, Inc. announced the completion of the Phase I trial of its NSI-566 spinal cord neural stem cells for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), with the eighteenth patient treated.

28 Aug 2012

Potential treatment for sleep disorders suffered by patients with Fibromyalgia, Post-Traumatic Stress Disorder and Traumatic Brain Injury

Seth Lederman, M.D., President and CEO of New York City-based Tonix Pharmaceuticals Holding Corp. (OTCBB:TNXP) says that a good night’s sleep is a potentially powerful, but currently elusive, treatment for the chronic pain and sleep disorders suffered by patients with fibromyalgia (FM), post-traumatic stress disorder (PTSD), traumatic brain injury (TBI) and chronic traumatic encephalopathy (CTE).

16 Aug 2012

Reducing copper in the body delays onset of prion disease

Many of us are familiar with prion disease from its most startling and unusual incarnations-the outbreaks of "mad cow" disease (bovine spongiform encephalopathy) that created a crisis in the global beef industry. Or the strange story of Kuru, a fatal illness affecting a tribe in Papua New Guinea known for its cannibalism. Both are forms of prion disease, caused by the abnormal folding of a protein and resulting in progressive neurodegeneration and death.

13 Aug 2012

Alfa Wassermann, Salix enter license agreement for EIR formulation of rifaximin

Salix Pharmaceuticals, Ltd. and Alfa Wassermann S.p.A. today announced that they have entered into an exclusive agreement by which Salix has licensed rights in the United States and Canada to an extended intestinal release (EIR) formulation of rifaximin for gastrointestinal and respiratory indications, including Crohn's disease.

9 Aug 2012

Hyperion Therapeutics announces completion of initial public offering

Hyperion Therapeutics, Inc. announced today the completion of its initial public offering of 5,000,000 shares of common stock.

31 Jul 2012

Latrepirdine appears effective in treating Alzheimer's disease in animals

An international team of scientists led by researchers at Mount Sinai School Medicine have discovered that a drug that had previously yielded conflicting results in clinical trials for Alzheimer's disease effectively stopped the progression of memory deterioration and brain pathology in mouse models of early stage Alzheimer's disease.

31 Jul 2012

Brain injury patterns predict outcomes in oxygen-starved infants

Patterns of brain injury in babies with neonatal hypoxic–ischemic encephalopathy predict survival and disability in late infancy, show study findings.

31 Jul 2012

Hyperion prices initial public offering of 5,000,000 shares of common stock

Hyperion Therapeutics, Inc. announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at $10.00 per share, before underwriting discounts and commissions.

26 Jul 2012

MRI infant prognosis unaffected by hypothermia

Magnetic resonance imaging is prognostic for newborn infants with hypoxic-ischemic encephalopathy regardless of treatment with hypothermia, research shows.

9 Jul 2012

KannaLife enters exclusive license with NIH-OTT for patent regarding cannabinoids

KannaLife Sciences, Inc. Signs Exclusive License Agreement With National Institutes of Health – Office of Technology Transfer for the Commercialization of U.S. Patent 6,630,507, "Cannabinoids as Antioxidants and Neuroprotectants".

9 Jul 2012

Does alcohol kill brain cells?

Several origins have been suggested for the idea that alcohol kills brain cells. Some link it to the temperance movement, which called for prohibition of alcohol.

9 Jul 2012

Neuralstem commences dosing in NSI-189 Phase Ib trial for major depressive disorder

Neuralstem, Inc. announced that the first patients were dosed in Phase Ib of its ongoing trial to test the safety of NSI-189 in the treatment of major depressive disorder (MDD).

25 Jun 2012

New BAP guidelines target treatment of substance abuse, addiction

The British Association for Psychopharmacology (BAP) has released fresh guidelines on the best methods to treat substance abuse and addiction in the Journal of Psychopharmacology, published by SAGE.

23 May 2012

Ocera’s Zysa receives CE Mark to treat IBS-d

Ocera Therapeutics Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary agents to treat gastrointestinal and liver diseases, announced today that it has received a CE Mark for Zysa (spherical carbon adsorbent, formerly AST-120) for the treatment of diarrhea predominant IBS (IBS-d), a condition affecting 10-15% of the Western world.

19 May 2012

Salix first quarter total product revenue increases 62% to $171.1M

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the first quarter ended March 31, 2012 and other business updates.

8 May 2012

Researchers discover how diabetes affects specific brain area leading to memory loss

Badly controlled diabetes are known to affect the brain causing memory and learning problems and even an increased incidence of dementia, although how this occurs is not clear.

7 May 2012

Repeated blows to the head associated with long term cognitive, pathologic changes

NFL great Junior Seau's apparent suicide might shock the sports world, but to neurosurgeons and neurologists accustomed to seeing an increase in the incidence of concussions, especially among football players, the news isn't as surprising.

3 May 2012

Kauffman Foundation sponsors National Conference on Value-driven Engineering

Researchers, health care engineers and medical device experts gathered this week for the inaugural National Conference on Value-driven Engineering to Improve Medical Innovation for U.S. Global Competitiveness assembled by the Austen BioInnovation Institute in Akron (ABIA) and sponsored by the Ewing Marion Kauffman Foundation.

30 Apr 2012